Health · 1 sources covering this

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

Great news for peptide fans: The Trump administration is giving the peptide craze a regulatory boost, despite objections from FDA career scientists.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
Great news for peptide fans: The Trump administration is giving the peptide craze a regulatory boost, despite objections from FDA career scientists.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/8006dd05aa8d48769563d70d1606b2553ddaed25"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: HHS green lights six peptides, despite concerns from FDA scientists"></iframe>

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

How 1 sources are covering this

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

More from Health

Martin Kulldorff critiques scientific gatekeepers at NIH lecture

STAT+: Vertex kidney disease drug scrutinized for infection risk

STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

More from Health

Martin Kulldorff critiques scientific gatekeepers at NIH lecture

STAT+: Vertex kidney disease drug scrutinized for infection risk

STAT+: Pharmalittle: We&#8217;re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more